Filgotinib Maleate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Filgotinib Maleate |
| DrugBank ID | DB14845 |
| Brand Names (EU) | Jyseleca |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.88% |
Approved Indication (EMA)
Rheumatoid arthritis Jyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX). Ulcerative colitis Jyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response wit
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | HER2 positive breast carcinoma | 98.88% | DL |
| 2 | thrombocytopenia | 98.87% | DL |
| 3 | hereditary thrombocytopenia with normal platelets | 98.85% | DL |
| 4 | marcothrombocytopenia with mitral valve insufficiency | 98.84% | DL |
| 5 | transient neonatal thrombocytopenia | 98.80% | DL |
| 6 | dense granule disease | 98.78% | DL |
| 7 | multiple endocrine neoplasia | 98.74% | DL |
| 8 | homozygous familial hypercholesterolemia | 98.33% | DL |
| 9 | progesterone-receptor negative breast cancer | 98.30% | DL |
| 10 | normal breast-like subtype of breast carcinoma | 98.29% | DL |
| 11 | progesterone-receptor positive breast cancer | 98.29% | DL |
| 12 | breast tumor luminal A or B | 98.28% | DL |
| 13 | oral candidiasis | 98.19% | DL |
| 14 | commissural lip fistula | 97.96% | DL |
| 15 | osteoradionecrosis of the mandible | 97.94% | DL |
| 16 | oral leukoedema | 97.92% | DL |
| 17 | burning mouth syndrome | 97.92% | DL |
| 18 | cytomegalovirus infection | 97.88% | DL |
| 19 | malignant catarrh | 97.85% | DL |
| 20 | infectious bovine rhinotracheitis | 97.85% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.